What began as research aimed at expanding the limited treatment options for cystinuria, a rare genetic disorder affecting 1 in every 7,000 people, characterized by the recurrent formation of cystine stones in the kidneys and urinary tract, could become a potential solution for millions of people worldwide affected by kidney stones (5%–10% of the global population).
Continue Reading this article here
